Literature DB >> 21953116

Inflammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer.

Sabina Davidsson1, Michelangelo Fiorentino, Ove Andrén, Fang Fang, Lorelei A Mucci, Eberhard Varenhorst, Katja Fall, Jennifer R Rider.   

Abstract

BACKGROUND: A challenge in prostate cancer (PCa) management is identifying potentially lethal disease at diagnosis. Inflammation, focal prostatic atrophy, and prostatic intraepithelial neoplasia (PIN) are common in prostate tumor specimens, but it is not clear whether these lesions have prognostic significance.
METHODS: We conducted a case-control study nested in a cohort of men diagnosed with stage T1a-b PCa through transurethral resection of the prostate in Sweden. Cases are men who died of PCa (n = 228). Controls are men who survived more than 10 years after PCa diagnosis without metastases (n = 387). Slides were assessed for Gleason grade, inflammation, PIN, and four subtypes of focal prostatic atrophy: simple atrophy (SA), postatrophic hyperplasia (PAH), simple atrophy with cyst formation, and partial atrophy. We estimated OR and 95% CI for odds of lethal PCa with multivariable logistic regression.
RESULTS: Chronic inflammation and PIN were more frequently observed in tumors with PAH, but not SA. No specific type of atrophy or inflammation was significantly associated with lethal PCa overall, but there was a suggestion of a positive association for chronic inflammation. Independent of age, Gleason score, year of diagnosis, inflammation, and atrophy type, men with PIN were 89% more likely to die of PCa (95% CI: 1.04-3.42).
CONCLUSION: Our data show that PIN, and perhaps presence of moderate or severe chronic inflammation, may have prognostic significance for PCa. IMPACT: Lesions in tumor adjacent tissue, and not just the tumor itself, may aid in identification of clinically relevant disease. ©2011 AACR

Entities:  

Mesh:

Year:  2011        PMID: 21953116      PMCID: PMC3671592          DOI: 10.1158/1055-9965.EPI-11-0373

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  36 in total

1.  Significance of focal proliferative atrophy lesions in prostate biopsy cores that test negative for prostate carcinoma.

Authors:  Anastasios D Asimakopoulos; Roberto Miano; Alessandro Mauriello; Sara Costantini; Patrizio Pasqualetti; Emanuele Liberati; Enrico Finazzi Agrò; Stefano Germani; Guido Virgili; Giuseppe Vespasiani
Journal:  Urol Oncol       Date:  2010-05-07       Impact factor: 3.498

Review 2.  EAU guidelines on prostate cancer.

Authors:  G Aus; C C Abbou; M Bolla; A Heidenreich; H-P Schmid; H van Poppel; J Wolff; F Zattoni
Journal:  Eur Urol       Date:  2005-10       Impact factor: 20.096

3.  Survival in prostate carcinoma--outcomes from a prospective, population-based cohort of 8887 men with up to 15 years of follow-up: results from three countries in the population-based National Prostate Cancer Registry of Sweden.

Authors:  Gunnar Aus; David Robinson; Johan Rosell; Gabriel Sandblom; Eberhard Varenhorst
Journal:  Cancer       Date:  2005-03-01       Impact factor: 6.860

4.  8p22 loss concurrent with 8c gain is associated with poor outcome in prostate cancer.

Authors:  J A Macoska; T M Trybus; K J Wojno
Journal:  Urology       Date:  2000-05       Impact factor: 2.649

5.  Postatrophic hyperplasia of the prostate gland: neoplastic precursor or innocent bystander?

Authors:  R Shah; N R Mucci; A Amin; J A Macoska; M A Rubin
Journal:  Am J Pathol       Date:  2001-05       Impact factor: 4.307

6.  Natural history of early, localized prostate cancer.

Authors:  Jan-Erik Johansson; Ove Andrén; Swen-Olof Andersson; Paul W Dickman; Lars Holmberg; Anders Magnuson; Hans-Olov Adami
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

7.  Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization.

Authors:  J Qian; D G Bostwick; S Takahashi; T J Borell; J F Herath; M M Lieber; R B Jenkins
Journal:  Cancer Res       Date:  1995-11-15       Impact factor: 12.701

8.  Plasma antibodies against Chlamydia trachomatis, human papillomavirus, and human herpesvirus type 8 in relation to prostate cancer: a prospective study.

Authors:  Siobhan Sutcliffe; Edward Giovannucci; Charlotte A Gaydos; Raphael P Viscidi; Frank J Jenkins; Jonathan M Zenilman; Lisa P Jacobson; Angelo M De Marzo; Walter C Willett; Elizabeth A Platz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-08       Impact factor: 4.254

Review 9.  Stem cell features of benign and malignant prostate epithelial cells.

Authors:  A M De Marzo; W G Nelson; A K Meeker; D S Coffey
Journal:  J Urol       Date:  1998-12       Impact factor: 7.450

10.  Prospective study of Trichomonas vaginalis infection and prostate cancer incidence and mortality: Physicians' Health Study.

Authors:  Jennifer R Stark; Gregory Judson; John F Alderete; Vasanthakrishna Mundodi; Ashwini S Kucknoor; Edward L Giovannucci; Elizabeth A Platz; Siobhan Sutcliffe; Katja Fall; Tobias Kurth; Jing Ma; Meir J Stampfer; Lorelei A Mucci
Journal:  J Natl Cancer Inst       Date:  2009-09-09       Impact factor: 13.506

View more
  31 in total

1.  Chronic Inflammation in Prostate Biopsy Cores is an Independent Factor that Lowers the Risk of Prostate Cancer Detection and is Inversely Associated with the Number of Positive Cores in Patients Elected to a First Biopsy.

Authors:  Antonio B Porcaro; Giovanni Novella; Daniele Mattevi; Leonardo Bizzotto; Giovanni Cacciamani; Nicolò De Luyk; Irene Tamanini; Maria A Cerruto; Matteo Brunelli; Walter Artibani
Journal:  Curr Urol       Date:  2016-05-20

Review 2.  Aspirin and urologic cancer risk: an update.

Authors:  Cristina Bosetti; Valentina Rosato; Silvano Gallus; Carlo La Vecchia
Journal:  Nat Rev Urol       Date:  2012-01-24       Impact factor: 14.432

3.  Interpathologist concordance in the histological diagnosis of focal prostatic atrophy lesions, acute and chronic prostatitis, PIN, and prostate cancer.

Authors:  Francesca Giunchi; Kristina Jordahl; Enrico Bollito; Maurizio Colecchia; Carlo Patriarca; Antonietta D'Errico; Francesco Vasuri; Deborah Malvi; Alessandro Fornari; Luca Reggiani Bonetti; Barbara Corti; Mauro Papotti; Paolo DeGiuli; Massimo Loda; Rodolfo Montironi; Michelangelo Fiorentino; Jennifer R Rider
Journal:  Virchows Arch       Date:  2017-04-12       Impact factor: 4.064

4.  Prostate cancer: intriguing data on inflammation and prostate cancer.

Authors:  Linda Vignozzi; Mario Maggi
Journal:  Nat Rev Urol       Date:  2014-07-01       Impact factor: 14.432

5.  Perineural Invasion and Risk of Lethal Prostate Cancer.

Authors:  Piotr Zareba; Richard Flavin; Masis Isikbay; Jennifer R Rider; Travis A Gerke; Stephen Finn; Andreas Pettersson; Francesca Giunchi; Robert H Unger; Alex M Tinianow; Swen-Olof Andersson; Ove Andrén; Katja Fall; Michelangelo Fiorentino; Lorelei A Mucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-01-06       Impact factor: 4.254

6.  A Prospective Study of Intraprostatic Inflammation, Focal Atrophy, and Progression to Lethal Prostate Cancer.

Authors:  Yiwen Zhang; Cindy Ke Zhou; Michelangelo Fiorentino; Ericka M Ebot; Emily M Rencsok; Katja Fall; Tamara L Lotan; Massimo Loda; Francesca Giunchi; Elizabeth A Platz; Angelo M De Marzo; Lorelei A Mucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-09-18       Impact factor: 4.254

7.  Infections and inflammation in prostate cancer.

Authors:  Karen S Sfanos; William B Isaacs; Angelo M De Marzo
Journal:  Am J Clin Exp Urol       Date:  2013-12-25

Review 8.  MSMB variation and prostate cancer risk: clues towards a possible fungal etiology.

Authors:  Siobhan Sutcliffe; Angelo M De Marzo; Karen S Sfanos; Martin Laurence
Journal:  Prostate       Date:  2014-01-24       Impact factor: 4.104

9.  Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial.

Authors:  Bora Gurel; M Scott Lucia; Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; Alan R Kristal; Howard L Parnes; Ashraful Hoque; Scott M Lippman; Siobhan Sutcliffe; Sarah B Peskoe; Charles G Drake; William G Nelson; Angelo M De Marzo; Elizabeth A Platz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-04-18       Impact factor: 4.254

10.  Intracellular location of BRCA2 protein expression and prostate cancer progression in the Swedish Watchful Waiting Cohort.

Authors:  Tryggvi Thorgeirsson; Kristina M Jordahl; Richard Flavin; Mara Meyer Epstein; Michelangelo Fiorentino; Swen-Olof Andersson; Ove Andren; Jennifer R Rider; Juan Miguel Mosquera; Helen Ingoldsby; Katja Fall; Laufey Tryggvadottir; Lorelei A Mucci
Journal:  Carcinogenesis       Date:  2016-01-16       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.